Two Sigma Advisers
GALT icon

Two Sigma Advisers’s Galectin Therapeutics GALT Stock Holding History

Two Sigma Advisers’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,900
Closed -$42K – 2465
2020
Q3 		$42K Buy
15,900
+4,100
+35% +$11.5K ﹤0.01% 2336
2020
Q2 		$36K Buy
+11,800
New +$29.7K ﹤0.01% 2439

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Advisers's GALT Position: Q4 2020 in Review

Two Sigma Advisers sold out of Galectin Therapeutics (GALT) in Q4 2020, closing a stake of 15,900 shares — an estimated $42K sold.

Two Sigma Advisers first reported a position in GALT in Q2 2020 and held it in 2 quarters. The position peaked at $42K in Q3 2020. 78 funds tracked by Wall St. Rank hold GALT as of Q4 2020.

  • Two Sigma Advisers reported no remaining Galectin Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Two Sigma Advisers sold 15,900 Galectin Therapeutics shares in Q4 2020, an estimated $42K.
  • Two Sigma Advisers first reported a position in Galectin Therapeutics in Q2 2020 and held it in 2 quarters.
  • Two Sigma Advisers's Galectin Therapeutics position peaked at $42K in Q3 2020.
  • 78 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2020.

Based on Two Sigma Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.